1. Home
  2. RHI vs TVTX Comparison

RHI vs TVTX Comparison

Compare RHI & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Robert Half Inc.

RHI

Robert Half Inc.

HOLD

Current Price

$42.49

Market Cap

4.5B

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$65.28

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RHI
TVTX
Founded
1948
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
5.3B
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
RHI
TVTX
Price
$42.49
$65.28
Analyst Decision
Hold
Strong Buy
Analyst Count
7
13
Target Price
$30.33
$40.62
AVG Volume (30 Days)
1.6M
1.2M
Earning Date
04-23-2026
05-04-2026
Dividend Yield
8.68%
N/A
EPS Growth
N/A
92.89
EPS
0.40
N/A
Revenue
$5,378,506,000.00
N/A
Revenue This Year
$1.27
$44.76
Revenue Next Year
$5.95
$35.51
P/E Ratio
$107.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.83
$22.06
52 Week High
$46.70
$68.03

Technical Indicators

Market Signals
Indicator
RHI
TVTX
Relative Strength Index (RSI) 51.96 60.45
Support Level $26.19 $53.76
Resistance Level $46.70 $66.24
Average True Range (ATR) 1.44 1.98
MACD -0.44 -0.14
Stochastic Oscillator 13.72 71.85

Price Performance

Historical Comparison
RHI
TVTX

About RHI Robert Half Inc.

Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: